Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cadonilimab in high-risk locoregionally-advanced nasopharyngeal carcinoma
NCT05587374Phase 3Active, not recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Aug 2023
- Primary completion
- Aug 2027
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of cadonilimab in nasopharyngeal carcinoma (NPC), sponsored by Sun Yat-sen University. Started Aug 2023; status: active, not recruiting.
02
Drugs
cadonilimab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT05587374.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05587374.